Study title: Efficacy of Symbicort® Turbuhaler® 160/4.5 µg as needed versus Oxis® 4.5 µg as needed and Bricanyl® 0.4 mg as needed in adults and adolescents with asthma receiving Symbicort® Turbuhaler® 160/4.5 µg twice daily as maintenance treatment. A 12-month, randomised, double-blind, parallel-group, active-controlled, phase IIIB, multi-centre study.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Respiratory Tract Diseases [C08] | |||||
Brands: | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: BUDESONIDE AND FORMOTEROL | |||||
ATC code: | |||||
Document link: LD-039-0003 CSR Synopsis.pdf | |||||
Document date: 2011-09-15 | |||||
Study number: LD-039-0003 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | Y |